Dasabuvir

• Description:

  Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC50 values of 7.7 and 1.8 nM, respectively[1].

• Product Name Alternative:

  ABT-333

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  DNA/RNA Synthesis; HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/ABT-333.html

• Purity:

  98.40

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  CS (=O) (NC1=CC=C2C=C (C3=CC (N (C (N4) =O) C=CC4=O) =CC (C (C) (C) C) =C3OC) C=CC2=C1) =O

• Molecular Formula:

  C26H27N3O5S

• Molecular Weight:

  493.57

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59 (3) :1505-11.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  1132935-63-7